4225-35-8

Basic information

• Product Name: 4,6-Dimethoxy-2,3-dihydrobenzofuran-3-one
• Synonyms: 4,6-Dimethoxy-2,3-dihydrobenzofuran-3-one;4,6-Dimethoxy-3(2H)-benzofuranone;4,6-Dimethoxybenzofuran-3(2H)-one;4,6-Dimethoxycoumaranone
• CAS NO: 4225-35-8
• Molecular Formula: C₁₀H₁₀O₄
• Molecular Weight: 194.18
• Mol File: 4225-35-8.mol
• Article Data: 23

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4,6-Dimethoxy-2,3-dihydrobenzofuran-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-Dimethoxy-2,3-dihydrobenzofuran-3-one(4225-35-8)
• EPA Substance Registry System: 4,6-Dimethoxy-2,3-dihydrobenzofuran-3-one(4225-35-8)

Safety Data

• Hazardous Substances Data: 4225-35-8(Hazardous Substances Data)

Upstream product

• 3260-49-9 4,6-dihydroxybenzofuran-3(2H)-one 
• 74-88-4 methyl iodide 
• 110865-03-7 2-chloro-1-(2,4,6-trihydroxyphenyl)ethan-1-one 
• 108-73-6 3,5-dihydroxyphenol 
• 18064-88-5 2-bromo-1-(2-hydroxy-4,6-dimethoxyphenyl)ethanone 
• 500-99-2 3,5-dimethoxyphenol 
• 107-14-2 chloroacetonitrile 
• 19728-23-5 2-(3,5-dimethoxyphenoxy)acetic acid 
• 553-86-6 benzofuran-2(3H)-one 
• 133156-39-5 3,5-Diacetoxy-2-ethoxycarbonylbenzylbromid 
• 28520-50-5 2,4-Diacetoxy-6-methylbenzoesaeureethylester 
• 2524-37-0 ethyl orselinate 
• 91570-58-0 5,7-diacetoxyphthalide 
• 77-78-1 dimethyl sulfate 

Downstream Products

• 1092706-09-6 C₂₂H₂₂O₆ 
• 109309-65-1 4,6-dimethoxy-2-(3'-methoxybenzylidene)benzofuran-3(2H)-one 
• 109309-38-8 4,6-dimethoxy-2-(2'-methoxybenzylidene)benzofuran-3(2H)-one 
• 1166399-26-3 4-hydroxy-7,9-dimethoxy-3-phenyl-2H-pyrano[3,2-b]benzofuran-2-one 
• 10493-04-6 4,6-dimethoxy-2-(4-methoxyphenylmethylene)benzofuran-3(2H)-one 
• 105098-40-6 (Z)-2-(2,4-dihydroxybenzylidene)-4,6-dihydroxybenzofuran-3(2H)-one 
• 1314713-81-9 (Z)-2-(4-cyclohexylbenzylidene)-4,6-dihydroxybenzofuran-3(2H)-one 
• 1314713-90-0 (Z)-2-(4-cyclohexylbenzylidene)-4,6-dimethoxybenzofuran-3(2H)-one 
• 480-70-6 aureusidin 
• 1314713-87-5 (Z)-2-(2,4-dimethylbenzylidene)-4,6-dimethoxybenzofuran-3(2H)-one 
• 109688-40-6 (Z)-2-(2,4-dimethoxybenzylidene)-4,6-dimethoxybenzofuran-3(2H)-one 

Relevant articles and documents

COMPOUNDS HAVING HEPATIAL DISEASE EFFECTIVE

The invention discloses a compound with a hepatopathy curative effect, and the compound is a compound shown as a general formula (I), an optical isomer or pharmaceutically acceptable salt thereof, canbe applied to treatment or prevention of hepatopathy, particularly to drugs for treating or preventing fatty liver, liver fibrosis or liver cirrhosis, and has a good application prospect.

Synthesis of structurally diverse biflavonoids

Synthetic biflavonoids are associated with interesting biological activities, yet they remain poorly explored within drug discovery. Recent years have witnessed a growing interest in synthetic approaches that can provide access to structurally novel biflavonoids so that the biological usefulness of this compound class can be more fully investigated. Herein, we report upon the exploration of strategies based around Suzuki-Miyaura cross-coupling and alcohol methylenation for the synthesis of two classes of biflavonoids: (i) rare ‘hybrid’ derivatives containing flavonoid monomers belonging to different subclasses, and (ii) homodimeric compounds in which the two flavonoid monomers are linked by a methylenedioxy group. Application of these strategies enabled the preparation of a structurally diverse collection of novel biflavonoids from readily-available starting materials, thereby facilitating the probing of uncharted regions of biologically interesting chemical space.

New pseudodimeric aurones as palm pocket inhibitors of Hepatitis C virus RNA-dependent RNA polymerase

The NS5B RNA-dependent RNA polymerase (RdRp) is a key enzyme for Hepatitis C Virus (HCV) replication. In addition to the catalytic site, this enzyme is characterized by the presence of at least four allosteric pockets making it an interesting target for development of inhibitors as potential anti-HCV drugs. Based on a previous study showing the potential of the naturally occurring aurones as inhibitors of NS5B, we pursued our efforts to focus on pseudodimeric aurones that have never been investigated so far. Hence, 14 original compounds characterized by the presence of a spacer between the benzofuranone moieties were synthesized and investigated as HCV RdRp inhibitors by means of an in vitro assay. The most active inhibitor, pseudodimeric aurone 4, induced high inhibition activity (IC50 Combining double low line 1.3 1/4M). Mutagenic and molecular modeling studies reveal that the binding site for the most active derivatives probably is the palm pocket I instead of the thumb pocket I as for the monomeric derivatives.